United Therapeutics (UTHR) Stock
Lung disease drug maker funding organ transplant research. Here's the price, business snapshot, and what's worth knowing about United Therapeutics in July 2026.
United Therapeutics Corporation (UTHR) is a US-based biotechnology company focused on therapies for pulmonary arterial hypertension (PAH) and related rare diseases. It markets prostacyclin-class and inhaled therapies across intravenous, oral and inhalation routes, generating recurring revenues from long-term treatments. The company also invests heavily in organ manufacturing and regenerative medicine — including xenotransplantation and bioengineered-lung research — targeting chronic transplant shortages. Its financial profile blends cash-generating marketed drugs with high-risk, high-reward R&D programmes. Key considerations for investors include clinical trial outcomes, regulatory approvals, pricing and reimbursement dynamics, and patent lifecycles. Market capitalisation is around $19.11 billion, reflecting both existing product cash flows and longer-term innovation hopes. This summary aims to inform and educate; it is not personalised investment advice. Values can fall as well as rise, and prospective investors should consider their own risk tolerance and seek independent advice where appropriate.
Why It’s Moving
Analysts tilt bullish on UTHR for 2026 as consensus price targets surge amid strong sector fundamentals
- Multiple analyst firms upgraded their consensus price targets for UTHR, with the average target exceeding $600, signaling robust expectations for future revenue growth and market expansion.
- Strong demand for the company's core biopharmaceutical products continues to drive earnings beats, reinforcing investor confidence in its ability to outpace sector competitors.
- Healthcare sector momentum remains intact, with macroeconomic stability and favorable policy environments supporting UTHR's long-term valuation trajectory and strategic positioning."],
Analysts tilt bullish on UTHR for 2026 as consensus price targets surge amid strong sector fundamentals
- Multiple analyst firms upgraded their consensus price targets for UTHR, with the average target exceeding $600, signaling robust expectations for future revenue growth and market expansion.
- Strong demand for the company's core biopharmaceutical products continues to drive earnings beats, reinforcing investor confidence in its ability to outpace sector competitors.
- Healthcare sector momentum remains intact, with macroeconomic stability and favorable policy environments supporting UTHR's long-term valuation trajectory and strategic positioning."],
When is the next earnings date for UNITED THERAPEUTICS CORP (UTHR)?
The next earnings report for United Therapeutics (UTHR) is expected on July 29, 2026, covering the second quarter of 2026. This date aligns with the company's historical reporting schedule for Q2, which typically occurs in late July. Please note that the company has not yet officially confirmed this specific date, so it remains an estimate based on prior patterns. No financial advice or price target recommendations are provided in this update.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying United Therapeutics' stock despite its current price being higher than the target.
Financial Health
United Therapeutics is performing well with strong profit margins and healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring UTHR
Drug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketUK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: 3 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pulmonary therapies
Established PAH medicines provide recurring revenue and clinical data; watch trial readouts and competition, though outcomes can vary.
Organ manufacturing
Work on xenotransplantation and bioengineered lungs targets a major unmet need, but timelines and regulatory paths are long and uncertain.
Commercial footing
A largely US-driven revenue base with growing international reach; pricing, patents and reimbursement will shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
